DE3907290A1
(de)
|
1989-03-07 |
1990-09-13 |
Gerhard Prof Dr Eisenbrand |
Steroidhormonrezeptoraffine antitumorwirkstoffe
|
AU696788B2
(en)
|
1994-06-27 |
1998-09-17 |
Neutron Therapies Inc. |
Boron-containing hormone analogs and methods of their use in imaging or killing cells having hormone receptors
|
AU691331B2
(en)
|
1994-08-12 |
1998-05-14 |
Myriad Genetics, Inc. |
Method for diagnosing a predisposition for breast and ovarian cancer
|
AU686004B2
(en)
|
1994-08-12 |
1998-01-29 |
Myriad Genetics, Inc. |
In vivo mutations and polymorphisms in the 17q-linked breast and ovarian cancer susceptibility gene
|
ATE307899T1
(de)
|
1994-11-01 |
2005-11-15 |
Ariad Gene Therapeutics Inc |
Neue methode zum auffindenund bewerten biologisch aktiver moleküle
|
US20030059465A1
(en)
|
1998-05-11 |
2003-03-27 |
Unger Evan C. |
Stabilized nanoparticle formulations of camptotheca derivatives
|
CZ2002711A3
(cs)
|
1999-08-27 |
2003-11-12 |
Ligand Pharmaceuticals Incorporated |
Modulátory androgenních receptorů, způsoby jejich výroby a způsoby jejich použití
|
KR100826485B1
(ko)
|
1999-10-14 |
2008-05-02 |
가켄 세야쿠 가부시키가이샤 |
테트라히드로퀴놀린 유도체
|
US7038041B2
(en)
|
2000-04-12 |
2006-05-02 |
The Trustees Of Boston University |
Selective nuclear receptor-targeted systems for delivery of cytotoxins to cancer cells for targeted photodynamic therapy
|
US7026500B2
(en)
|
2000-08-24 |
2006-04-11 |
University Of Tennessee Research Foundation |
Halogenated selective androgen receptor modulators and methods of use thereof
|
CA2422137A1
(en)
|
2000-09-14 |
2003-03-13 |
Kaken Pharmaceutical Co., Ltd. |
Tetrahydroquinoline compounds
|
ES2291507T3
(es)
|
2001-10-19 |
2008-03-01 |
MERCK & CO., INC. |
Moduladores de receptor de androgenos y procedimientos de uso de los mismos.
|
IL148825A0
(en)
|
2002-03-21 |
2002-09-12 |
Yeda Res & Dev |
Derivatives of isoflavones
|
ITRM20020305A1
(it)
|
2002-05-31 |
2003-12-01 |
Sigma Tau Ind Farmaceuti |
Camptotecine con anello lattonico modificato.
|
JPWO2004000816A1
(ja)
|
2002-06-19 |
2005-10-20 |
科研製薬株式会社 |
アンドロゲン受容体アゴニスト
|
US20050277660A1
(en)
|
2002-08-01 |
2005-12-15 |
Motonori Miyakawa |
Novel tetrahydroquinoline derivatives
|
JP2006513159A
(ja)
|
2002-11-01 |
2006-04-20 |
メルク エンド カムパニー インコーポレーテッド |
アンドロゲン受容体モジュレーターとしてのカルボニルアミノ−ベンズイミダゾール誘導体
|
US8420086B2
(en)
|
2002-12-13 |
2013-04-16 |
Immunomedics, Inc. |
Camptothecin conjugates of anti-CD22 antibodies for treatment of B cell diseases
|
PL1633724T3
(pl)
|
2003-03-12 |
2011-10-31 |
Kudos Pharm Ltd |
Pochodne ftalazynonu
|
GB0305681D0
(en)
|
2003-03-12 |
2003-04-16 |
Kudos Pharm Ltd |
Phthalazinone derivatives
|
US7449464B2
(en)
|
2003-03-12 |
2008-11-11 |
Kudos Pharmaceuticals Limited |
Phthalazinone derivatives
|
US8709998B2
(en)
|
2003-04-22 |
2014-04-29 |
Ipsen Pharma S.A.S. |
Peptide vectors
|
WO2005000795A2
(en)
|
2003-06-10 |
2005-01-06 |
Smithkline Beecham Corporation |
Aniline derivatived androgen-, glucocorticoid-, mineralcorticoid- and progesterone- receptor modulators
|
JP2007505164A
(ja)
|
2003-06-10 |
2007-03-08 |
スミスクライン ビーチャム コーポレーション |
アンドロゲン、グルココルチコイド、ミネラルコルチコイドおよびプロゲステロン受容体のモジュレーターとしての1−アミノナフタレン類
|
DK1656360T3
(da)
|
2003-06-13 |
2007-12-27 |
Janssen Pharmaceutica Nv |
Thiazolinderivater som selektive androgenreceptor-modulatorer
|
US20070275911A1
(en)
|
2003-09-05 |
2007-11-29 |
Koch Tad H |
Targeted Drug-Formaldehyde Conjugates and Methods of Making and Using the Same
|
US7220730B2
(en)
|
2003-09-25 |
2007-05-22 |
Board Of Regents Of The University Of Nebraska |
Cancer specific radiolabeled conjugates regulated by the cell cycle for the treatment and diagnosis of cancer
|
CA2547077C
(en)
|
2003-12-01 |
2015-11-03 |
Kudos Pharmaceuticals Limited |
Dna damage repair inhibitors for treatment of cancer
|
EP1725522B1
(en)
|
2004-03-03 |
2014-09-10 |
GlaxoSmithKline LLC |
Aniline derivatives as selective androgen receptor modulators
|
WO2005086974A2
(en)
|
2004-03-10 |
2005-09-22 |
Massachusetts Institute Of Technology |
Methods and compositions for treating cancer
|
AU2005243238B2
(en)
|
2004-05-03 |
2011-11-10 |
Janssen Pharmaceutica N.V. |
Novel indole derivatives as selective androgen receptor modulators (SARMS)
|
CN1980917B
(zh)
|
2004-05-03 |
2014-02-12 |
詹森药业有限公司 |
作为选择性雄激素受体调节剂(sarms)的新的吲哚衍生物
|
US20080045504A1
(en)
|
2004-05-11 |
2008-02-21 |
Pfizer Products Inc. |
Benzonitrile Derivatives to Treat Musculoskeletal Frailty
|
ZA200610270B
(en)
|
2004-05-17 |
2008-06-25 |
Acadia Pharm Inc |
Androgen receptor modulators and method of treating disease using the same
|
WO2005118612A1
(en)
|
2004-06-04 |
2005-12-15 |
Sonus Pharmaceuticals, Inc. |
Cholesterol/bile acid/bile acid derivative-modified therapeutic anti-cancer drugs
|
UA87854C2
(en)
|
2004-06-07 |
2009-08-25 |
Мерк Энд Ко., Инк. |
N-(2-benzyl)-2-phenylbutanamides as androgen receptor modulators
|
AU2005285035B2
(en)
|
2004-09-10 |
2012-03-22 |
Janssen Pharmaceutica N.V. |
Novel imidazolidin-2-one derivatives as selective androgen receptor modulators (SARMS)
|
WO2006044707A1
(en)
|
2004-10-13 |
2006-04-27 |
Smithkline Beecham Corporation |
Chemical compounds
|
CA2585276A1
(en)
|
2004-10-29 |
2006-06-08 |
Merck & Co., Inc. |
N-(pyridin-3-yl)-2-phenylbutanamides as androgen receptor modulators
|
CA2587678C
(en)
|
2004-11-16 |
2013-05-21 |
Janssen Pharmaceutica N.V. |
Novel heterocycle derivatives useful as selective androgen receptor modulators (sarms)
|
JP5203712B2
(ja)
|
2005-01-10 |
2013-06-05 |
アカディア ファーマシューティカルズ インコーポレイテッド |
選択的アンドロゲン受容体モジュレータとしてのアミノフェニル誘導体
|
PL1891038T3
(pl)
|
2005-05-13 |
2009-04-30 |
Lilly Co Eli |
Podstawione n-arylopirolidyny jako selektywne modulatory receptora androgenowego
|
WO2006133216A2
(en)
|
2005-06-06 |
2006-12-14 |
Smithkline Beecham Corporation |
4-substituted arylamine derivatives and their use in pharmaceutical compositions
|
EP1902026B1
(en)
|
2005-06-24 |
2010-02-17 |
Eli Lilly And Company |
Tetrahydrocarbazole derivatives useful as androgen receptor modulators (sarm)
|
US20070122843A1
(en)
|
2005-09-23 |
2007-05-31 |
Fazlul Sarkar |
Isoflavonoid analogs and their metal complexes as anti-cancer agents
|
GB0701273D0
(en)
|
2007-01-24 |
2007-02-28 |
Angeletti P Ist Richerche Bio |
New compounds
|
WO2009005839A2
(en)
|
2007-07-03 |
2009-01-08 |
The Government Of The U.S.A. As Represented By The Secretary Of The Dept. Of Health & Human Service |
Compounds and methods of use
|
US20090062268A1
(en)
|
2007-08-27 |
2009-03-05 |
Lead Therapeutics, Inc. |
Novel inhibitors of poly(adp-ribose)polymerase (parp)
|
GB0718045D0
(en)
|
2007-09-14 |
2007-10-24 |
Peptcell Ltd |
Pharmaceutical compound
|
CN101917982B
(zh)
|
2007-11-12 |
2013-03-20 |
彼帕科学公司 |
使用4-碘-3-硝基苯甲酰胺与抗肿瘤剂组合治疗乳腺癌
|
WO2009088860A2
(en)
|
2007-12-31 |
2009-07-16 |
Inotek Pharmaceuticals Corporation |
A method of preventing contrast-induced nephropathy
|
UY31603A1
(es)
|
2008-01-23 |
2009-08-31 |
|
Derivados de ftalazinona
|
US8268872B2
(en)
|
2008-02-22 |
2012-09-18 |
Radius Health, Inc. |
Selective androgen receptor modulators
|
WO2009114459A2
(en)
|
2008-03-10 |
2009-09-17 |
The Trustees Of The University Of Pennsylvania |
Anti-neoplastic combination therapeutic regimen involving co-disruption of parp pathway and mre11/rad50/nbs1 complex and compositons useful therein
|
US20110028420A1
(en)
|
2008-04-10 |
2011-02-03 |
Boulares Hamid A |
Regression of Established Atherosclerotic Plaques, and Treating Sudden-Onset Asthma Attacks, using PARP Inhibitors
|
US20110104074A1
(en)
|
2008-06-18 |
2011-05-05 |
University Of Louisville Research Foundation, Inc. |
Methods for targeted cancer treatment and detection
|
EP2326650B9
(en)
|
2008-08-06 |
2014-09-10 |
BioMarin Pharmaceutical Inc. |
Dihydropyridophthalazinone inhibitors of poly(adp-ribose)polymerase (parp)
|
US20110053923A1
(en)
|
2008-12-22 |
2011-03-03 |
Astrazeneca |
Chemical compounds 610
|
WO2010085747A1
(en)
|
2009-01-23 |
2010-07-29 |
Northeastern University |
Steroidal anti-hormone hybrids
|
BRPI0901157A2
(pt)
|
2009-03-27 |
2010-11-16 |
Univ Fed Pernambuco |
complexo molecular antineoplásico-testosterona
|
CA2775266C
(en)
|
2009-10-13 |
2013-12-31 |
Duquesne University Of The Holy Spirit, A Nonprofit Corporation Organized Under The Laws Of The Commonwealth Of Pennsylvania |
Anti-cancer tamoxifen-melatonin hybrid ligand
|
CA2785395A1
(en)
|
2009-12-23 |
2011-06-30 |
Board Of Regents Of The University Of Nebraska |
Targeted radiolabeled compounds and their use for the treatment and diagnosis of cancer
|
EP2558506B1
(en)
|
2010-04-16 |
2019-06-26 |
Momenta Pharmaceuticals, Inc. |
Tissue targeting
|
SA111320519B1
(ar)
|
2010-06-11 |
2014-07-02 |
Astrazeneca Ab |
مركبات بيريميدينيل للاستخدام كمثبطات atr
|
EP2598491B1
(en)
|
2010-07-27 |
2015-09-02 |
Cadila Healthcare Limited |
Substituted 4-(4-fluoro-3-(piperazine-1- carbonyl)benzyl)phthalazin-1(2h)-one derivatives as poly (adp-ribose) polymerase- 1 inhibitors
|
CN101967172A
(zh)
|
2010-09-15 |
2011-02-09 |
东北林业大学 |
喜树碱10位偶合胆酸的新衍生物
|
CN101967173A
(zh)
|
2010-09-15 |
2011-02-09 |
东北林业大学 |
喜树碱10位偶合胆酸的新衍生物
|
CN101948500A
(zh)
|
2010-09-15 |
2011-01-19 |
东北林业大学 |
喜树碱20位偶合胆酸的新衍生物
|
US9139565B2
(en)
|
2010-09-28 |
2015-09-22 |
Georgia Tech Research Corporation |
Histone deacetylase (HDAC) inhibitors targeting prostate tumors and methods of making and using thereof
|
WO2012074840A2
(en)
|
2010-11-22 |
2012-06-07 |
The General Hospital Corporation |
Compositions and methods for in vivo imaging
|
US20140088178A1
(en)
|
2011-03-14 |
2014-03-27 |
The University Of British Columbia |
Combination of anti-clusterin oligonucleotide with androgen receptor antagonist for the treatment of prostate cancer
|
WO2012134446A1
(en)
|
2011-03-29 |
2012-10-04 |
SUTTER WEST BAY HOSPITALS doing business as CALIFORNIA PACIFIC MEDICAL CENTER |
Epiandrosterone and/or androsterone derivatives and method of use thereof
|
WO2013028495A1
(en)
|
2011-08-19 |
2013-02-28 |
Biomarin Pharmaceutical Inc. |
Dihydropyridophthalazinone inhibitors of poly (adp-ribose) polymerase (parp) for the treatment of multiple myeloma
|
JP5934986B2
(ja)
|
2011-09-07 |
2016-06-15 |
公益財団法人ヒューマンサイエンス振興財団 |
アポトーシス阻害タンパク質リガンド−エストロゲン受容体リガンドハイブリッド化合物並びにそれを利用したエストロゲン受容体分解誘導剤及び乳癌、子宮頚癌又は卵巣癌の予防及び治療剤
|
CN102492010A
(zh)
|
2011-12-15 |
2012-06-13 |
东北林业大学 |
喜树碱20位胆酸衍生物及其制备方法
|
CN102492009A
(zh)
|
2011-12-15 |
2012-06-13 |
东北林业大学 |
喜树碱20位胆酸衍生物及其制备方法
|
CN102532237A
(zh)
|
2011-12-15 |
2012-07-04 |
东北林业大学 |
喜树碱10位胆酸偶合物及其制备方法
|
CN102516347A
(zh)
|
2011-12-15 |
2012-06-27 |
东北林业大学 |
喜树碱20位胆酸衍生物及其制备方法
|
CN104736569A
(zh)
|
2012-01-12 |
2015-06-24 |
耶鲁大学 |
通过e3泛素连接酶增强靶蛋白质及其他多肽降解的化合物和方法
|
WO2013166110A1
(en)
|
2012-05-02 |
2013-11-07 |
Yale University |
Tlr-agonist-conjugated antibody recruiting molecules (tlr_arms)
|
WO2013170147A1
(en)
|
2012-05-11 |
2013-11-14 |
Yale University |
Compounds useful for promoting protein degradation and methods using same
|
BR112014031421A2
(pt)
|
2012-06-15 |
2017-06-27 |
Brigham & Womens Hospital Inc |
composições para tratamento de câncer e métodos para produção das mesmas
|
US11873281B2
(en)
|
2012-07-12 |
2024-01-16 |
Hangzhou Dac Biotech Co., Ltd. |
Conjugates of cell binding molecules with cytotoxic agents
|
US9969683B2
(en)
|
2012-07-13 |
2018-05-15 |
Gtx, Inc. |
Method of treating estrogen receptor (ER)-positive breast cancers with selective androgen receptor modulator (SARMS)
|
US10987334B2
(en)
|
2012-07-13 |
2021-04-27 |
University Of Tennessee Research Foundation |
Method of treating ER mutant expressing breast cancers with selective androgen receptor modulators (SARMs)
|
AU2012395148B2
(en)
|
2012-11-24 |
2016-10-27 |
Hangzhou Dac Biotech Co., Ltd. |
Hydrophilic linkers and their uses for conjugation of drugs to cell binding molecules
|
GB201311910D0
(en)
|
2013-07-03 |
2013-08-14 |
Glaxosmithkline Ip Dev Ltd |
Novel Compounds
|
UY35590A
(es)
|
2013-05-28 |
2014-11-28 |
Astrazeneca Ab |
Nuevos compuestos para el tratamiento del cáncer
|
WO2014201026A2
(en)
|
2013-06-10 |
2014-12-18 |
Cedars-Sinai Medical Center |
Antioxidant, anti-inflammatory and anticancer derivatives of triptolide and nanospheres thereof
|
CN104292290A
(zh)
|
2013-07-16 |
2015-01-21 |
中国人民解放军军事医学科学院毒物药物研究所 |
以氨基酸为连接子的胆汁酸-药物偶合物及其医药用途
|
WO2015038649A1
(en)
|
2013-09-10 |
2015-03-19 |
Synta Pharmaceuticals Corp. |
Targeted therapeutics
|
IL290330B2
(en)
|
2013-12-19 |
2023-09-01 |
Seagen Inc |
Methylene carbamate binders for use with drug-targeting conjugates
|
CN106456795A
(zh)
|
2014-03-03 |
2017-02-22 |
辛塔医药品有限公司 |
靶向治疗学
|
MA39483A
(fr)
|
2014-03-18 |
2015-09-24 |
Synta Pharmaceuticals Corp |
Agents thérapeutiques cibles
|
US20160058872A1
(en)
|
2014-04-14 |
2016-03-03 |
Arvinas, Inc. |
Imide-based modulators of proteolysis and associated methods of use
|
US20180228907A1
(en)
|
2014-04-14 |
2018-08-16 |
Arvinas, Inc. |
Cereblon ligands and bifunctional compounds comprising the same
|
CN105315294B
(zh)
|
2014-06-26 |
2018-05-01 |
王杭祥 |
7-乙基-10-羟基喜树碱药物前体及其制备方法和应用
|
WO2016025480A1
(en)
|
2014-08-11 |
2016-02-18 |
The General Hospital Corporation |
Cyclooctenes for bioorthogonol reactions
|
US20180125988A1
(en)
|
2014-11-11 |
2018-05-10 |
Amunix Operating Inc. |
Targeted xten conjugate compositions and methods of making same
|
US9694084B2
(en)
|
2014-12-23 |
2017-07-04 |
Dana-Farber Cancer Institute, Inc. |
Methods to induce targeted protein degradation through bifunctional molecules
|
KR102564925B1
(ko)
|
2015-01-20 |
2023-08-07 |
아비나스 오퍼레이션스, 인코포레이티드 |
안드로겐 수용체의 표적화된 분해를 위한 화합물 및 방법
|
US20170327469A1
(en)
|
2015-01-20 |
2017-11-16 |
Arvinas, Inc. |
Compounds and methods for the targeted degradation of androgen receptor
|
CA2979070A1
(en)
|
2015-03-18 |
2016-09-22 |
Arvinas, Inc. |
Compounds and methods for the enhanced degradation of targeted proteins
|
PE20181083A1
(es)
|
2015-05-29 |
2018-07-05 |
Eisai Randd Man Co Ltd |
Compuestos alqueno tetrasustituidos y su uso
|
CN108136044B
(zh)
|
2015-06-04 |
2021-08-10 |
阿尔维纳斯运营股份有限公司 |
基于酰亚胺的蛋白水解调节剂和相关使用方法
|
US20180147202A1
(en)
|
2015-06-05 |
2018-05-31 |
Arvinas, Inc. |
TANK-BINDING KINASE-1 PROTACs AND ASSOCIATED METHODS OF USE
|
AU2015242210A1
(en)
|
2015-06-15 |
2017-12-07 |
Hangzhou Dac Biotech Co., Ltd |
Hydrophilic linkers for conjugation
|
US10975112B2
(en)
|
2015-06-16 |
2021-04-13 |
Hangzhou Dac Biotech Co., Ltd. |
Linkers for conjugation of cell-binding molecules
|
EP3317246A4
(en)
|
2015-07-04 |
2019-02-27 |
Suzhou M-conj Biotech Co., Ltd. |
SPECIFIC CONJUGATION OF A CELL BINDING MOLECULE
|
MX2018000360A
(es)
|
2015-07-10 |
2018-06-11 |
Arvinas Inc |
Moduladores basados en mdm2 de proteolisis y metodos de uso asociados.
|
CA2991973C
(en)
|
2015-07-12 |
2021-12-07 |
Suzhou M-Conj Biotech Co., Ltd. |
Bridge linkers for conjugation of a cell-binding molecule
|
EP3322986A4
(en)
|
2015-07-13 |
2018-09-05 |
Arvinas, Inc. |
Alanine-based modulators of proteolysis and associated methods of use
|
US9839687B2
(en)
|
2015-07-15 |
2017-12-12 |
Suzhou M-Conj Biotech Co., Ltd. |
Acetylenedicarboxyl linkers and their uses in specific conjugation of a cell-binding molecule
|
JP6817288B2
(ja)
|
2015-08-10 |
2021-01-20 |
ハンジョウ ディーエーシー バイオテック シーオー.,エルティディ.Hangzhou Dac Biotech Co.,Ltd. |
新規な連結体及び生体分子と薬物との特異的共役におけるその使用
|
WO2017075495A1
(en)
|
2015-10-28 |
2017-05-04 |
Tarveda Therapeutics, Inc. |
Sstr-targeted conjugates and particles and formulations thereof
|
US9963433B2
(en)
|
2016-01-29 |
2018-05-08 |
Wayne State University |
Anticancer drugs including the chemical structures of an androgen receptor ligand and a histone deacetylase inhibitor
|
CA3013412C
(en)
|
2016-02-04 |
2023-10-10 |
Suzhou M-Conj Biotech Co., Ltd. |
Specific conjugation linkers, specific immunoconjugates thereof, methods of making and uses such conjugates thereof
|
JP2019094260A
(ja)
|
2016-03-28 |
2019-06-20 |
国立大学法人東北大学 |
癌疾患治療用ナノ粒子化製剤
|
CN107286166B
(zh)
|
2016-04-11 |
2020-03-31 |
上海勋和医药科技有限公司 |
取代1,3,4,5-四氢-6h-吡咯并[4,3,2-ef][2]苯并氮杂-6-酮衍生物
|
GB201608885D0
(en)
|
2016-05-20 |
2016-07-06 |
Univ Birmingham |
Treatment
|
CN109475567A
(zh)
|
2016-06-09 |
2019-03-15 |
布兰克生物股份有限公司 |
基于硅烷醇的治疗有效载荷
|
US10054602B2
(en)
|
2016-08-19 |
2018-08-21 |
Christ University |
Conjugate of estradiol and applications thereof
|
CN109563080B
(zh)
|
2016-08-24 |
2021-07-30 |
台湾神隆股份有限公司 |
奥拉帕尼的制备方法
|
AU2017341723B2
(en)
|
2016-10-11 |
2021-12-16 |
Arvinas Operations, Inc. |
Compounds and methods for the targeted degradation of androgen receptor
|
EP3554526B1
(en)
|
2016-12-14 |
2024-05-08 |
Purdue Research Foundation |
Luteinizing hormone-releasing hormone receptor (lhrh-r) conjugates and uses thereof
|
BR112019012878A2
(pt)
|
2016-12-23 |
2019-11-26 |
Arvinas Operations Inc |
compostos e métodos para a degradação alvo de polipeptídos de fibrossarcoma rapidamente acelerados
|
BR112019015484A2
(pt)
|
2017-01-31 |
2020-04-28 |
Arvinas Operations Inc |
ligantes de cereblon e compostos bifuncionais compreendendo os mesmos
|
AU2018225177A1
(en)
|
2017-02-23 |
2019-09-05 |
Rakuten Medical, Inc. |
Therapeutic compositions and related methods for photoimmunotherapy
|
CA3058712C
(en)
|
2017-04-06 |
2023-04-18 |
Hangzhou Dac Biotech Co., Ltd |
Conjugation of a cytotoxic drug with bis-linkage
|
ES2930276T3
(es)
|
2017-06-21 |
2022-12-09 |
Glykos Finland Oy |
Enlazadores hidrofílicos y conjugados de los mismos
|
CN107266520A
(zh)
|
2017-06-28 |
2017-10-20 |
湖南华腾制药有限公司 |
一种喜树碱与桦木酸结合物及其制备方法
|
RU2020108515A
(ru)
|
2017-07-28 |
2021-08-27 |
Эрвинэс Оперейшнс, Инк. |
Соединения и способы целевого расщепления андрогенного рецептора
|
CN108014347B
(zh)
|
2017-11-23 |
2021-05-04 |
金志明 |
一种谷氨酸多肽-雌激素/抗雌激素缀合物、合成方法、组合物及试剂盒
|
EP3773727A4
(en)
|
2018-04-09 |
2022-05-04 |
Yale University |
BIFUNCTIONAL SMALL MOLECULES TO TARGETING THE SELECTIVE DEGRADATION OF CIRCULATING PROTEINS
|
CN112262134B
(zh)
|
2018-04-13 |
2024-05-24 |
阿尔维纳斯运营股份有限公司 |
小脑蛋白配体和包括其的双官能化合物
|
US20190375732A1
(en)
|
2018-05-14 |
2019-12-12 |
David Hung |
Anti-cancer nuclear hormone receptor-targeting compounds
|
WO2019241231A1
(en)
|
2018-06-11 |
2019-12-19 |
Abhishek Sharma |
Antiestrogen compounds
|
WO2020023851A1
(en)
|
2018-07-26 |
2020-01-30 |
Yale University |
Bifunctional substitued pyrimidines as modulators of fak proteolyse
|
WO2020113094A1
(en)
|
2018-11-30 |
2020-06-04 |
Nuvation Bio Inc. |
Pyrrole and pyrazole compounds and methods of use thereof
|
EP3886853A4
(en)
|
2018-11-30 |
2022-07-06 |
Nuvation Bio Inc. |
DIARYLHYDANTOI COMPOUNDS AND METHODS OF USE THEREOF
|
US11478493B2
(en)
|
2019-03-08 |
2022-10-25 |
University Of South Carolina |
Fabrication and application of a hetero-targeted nano-cocktail with traceless linkers
|
US20200297725A1
(en)
|
2019-03-22 |
2020-09-24 |
Yale University |
Allosteric bcr-abl proteolysis targeting chimeric compounds
|
AU2020274113A1
(en)
|
2019-05-14 |
2021-11-11 |
Nuvation Bio Inc. |
Anti-cancer nuclear hormone receptor-targeting compounds
|
MX2021015887A
(es)
|
2019-06-24 |
2022-03-22 |
Hangzhou Dac Biotech Co Ltd |
Un conjugado de un agente citotóxico y una molécula de unión a células con enlazadores ramificados.
|
US11325906B2
(en)
|
2019-07-19 |
2022-05-10 |
Astrazeneca Ab |
Chemical compounds
|
EP4031543A4
(en)
|
2019-09-18 |
2023-09-27 |
The Regents Of The University Of California |
BIAMINOQUINOLINES AND NANOFORMULATIONS FOR THE TREATMENT OF CANCER
|
US11952349B2
(en)
|
2019-11-13 |
2024-04-09 |
Nuvation Bio Inc. |
Anti-cancer nuclear hormone receptor-targeting compounds
|
WO2021127443A1
(en)
|
2019-12-19 |
2021-06-24 |
Arvinas Operations, Inc. |
Compounds and methods for the targeted degradation of androgen receptor
|
IL299001A
(en)
|
2020-06-19 |
2023-02-01 |
Hangzhou Dac Biotech Co Ltd |
Pairings of a cell-binding molecule with camptocin analogs
|
CA3187253A1
(en)
|
2020-08-11 |
2022-02-17 |
Reynold Homan |
Peptides and formulations for cancer treatment
|
JP2023538133A
(ja)
|
2020-08-21 |
2023-09-06 |
ザ ユニバーシティ オブ シカゴ |
がん治療のための複数の切断可能なプロドラッグを含むナノ粒子
|
IL302137A
(en)
|
2020-10-21 |
2023-06-01 |
Arvinas Operations Inc |
Compounds and methods for targeted degradation of androgen receptor protein
|
WO2022098544A1
(en)
|
2020-11-06 |
2022-05-12 |
Arvinas Operations, Inc. |
Compounds and methods for the targeted degradation of androgen receptor and associated methods of use
|
WO2022228387A1
(en)
|
2021-04-26 |
2022-11-03 |
Fochon Biosciences, Ltd. |
Compounds as parp inhibitors
|
IL308104A
(en)
|
2021-05-03 |
2023-12-01 |
Nuvation Bio Inc |
Nuclear hormone receptor-targeted compounds against cancer
|